Lastly, we found that a combined therapy involving inhibition of both DNA methylation and the PD-L1 immune checkpoint improves survival in our mouse model of CRC, suggesting that such combined therapies may hold clinical promises for CRC patients with p16 epimutation. The gene discussed is CDKN2A; the disease is colorectal carcinoma.